Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179843
Title: | Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson’s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up |
Author: | Santos García, D. De Deus, Teresa Cores, Carlos Canfield, Hector Paz González, Jose Martínez Miró, Cristina Valdés Aymerich, Lorena Suárez, Ester Jesús, Silvia Aguilar, Miquel Pastor, Pau Planellas, Lluís Cosgaya, Marina García Caldentey, Juan Caballol, Núria Legarda, Ines Hernández-Vara, Jorge Cabo, Iria López Manzanares, Lydia González Aramburu, Isabel Ávila Rivera, Maria Asunción Catalán, Maria Nogueira, Victor Puente, Victor Dotor, Julio Borrué, Carmen Solano, Berta Álvarez Sauco, Maria Vela, Lydia Escalante, Sonia Cubo, Esther Carrillo, Francisco Martínez Castrillo, Juan Sánchez Alonso, Pilar Alonso, Gemma López Ariztegui, Nuria Gastón, Itziar Kulisevsky, Jaime Blázquez, Marta Seijo Martínez, Manuel Rúiz Martínez, Javier Valero, Caridad Kurtis, Monica Fábregues, Oriol de Ardura, Jessica Alonso, Ruben Ordás, Carlos López Díaz, Luis Mcafee, Darrian Martinez-Martin, Pablo Mir, Pablo Coppadis Study Group |
Keywords: | Malaltia de Parkinson Parkinson's disease |
Issue Date: | 30-Jun-2021 |
Publisher: | MDPI AG |
Abstract: | Background and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson's disease (PD) patients. The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group, and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods: PD patients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months ± 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PD patients by 18.8% (from 45.08 ± 37.62 to 53.55 ± 42.28; p < 0.0001; N = 501; 60.2% males, mean age 62.59 ± 8.91) compared to no change observed in controls (from 14.74 ± 18.72 to 14.65 ± 21.82; p = 0.428; N = 122; 49.5% males, mean age 60.99 ± 8.32) (p < 0.0001). NMSS total score at baseline (β = -0.52), change from V0 to V2 in PDSS (Parkinson's Disease Sleep Scale) (β = -0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory) (β = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PD patients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/jpm11070626 |
It is part of: | Journal of Personalized Medicine, 2021, vol. 11, issue. 7, p. 626-651 |
URI: | http://hdl.handle.net/2445/179843 |
Related resource: | https://doi.org/10.3390/jpm11070626 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jpm-11-00626-v2.pdf | 1.15 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License